NASDAQ:MNKD - MannKind Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.93 -0.01 (-0.52 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.94
Today's Range$1.89 - $1.98
52-Week Range$1.09 - $6.96
Volume1.34 million shs
Average Volume3.19 million shs
Market Capitalization$271.65 million
P/E Ratio-1.66
Dividend YieldN/A
Beta2.92

About MannKind (NASDAQ:MNKD)

MannKind logoMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000

Debt

Debt-to-Equity Ratio-0.43
Current Ratio0.43
Quick Ratio0.39

Price-To-Earnings

Trailing P/E Ratio-1.66
Forward P/E Ratio-2.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.74 million
Price / Sales23.02
Cash FlowN/A
Price / CashN/A
Book Value($1.59) per share
Price / Book-1.21

Profitability

EPS (Most Recent Fiscal Year)($1.16)
Net Income$-117,330,000.00
Net Margins-1,076.91%
Return on EquityN/A
Return on Assets-185.01%

Miscellaneous

Employees250
Outstanding Shares140,020,000

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The biopharmaceutical company had revenue of $3.47 million for the quarter, compared to analysts' expectations of $3.53 million. During the same period last year, the business earned ($0.17) EPS. View MannKind's Earnings History.

When is MannKind's next earnings date?

MannKind is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for MannKind.

What price target have analysts set for MNKD?

2 analysts have issued 1-year price objectives for MannKind's shares. Their predictions range from $1.00 to $5.00. On average, they anticipate MannKind's stock price to reach $2.9233 in the next year. View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:
  • 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (5/24/2018)
  • 2. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) $324.5 Market Cap (M) $238 Shares Outstanding (M) 133.1 3 Interest (M) 32.53 Cash (M) $53.5 Total Debt (M) $140.0 Year – (0.15) FY (1.13) (0.83) (0.65) FY P/E NM NM NM Year – 14.7 FY 11.7 20.8 45.4 8 6 4 2 0 0 Vol. (mil) the science to drive Afrezza awareness and adoption." (5/10/2018)

Are investors shorting MannKind?

MannKind saw a decrease in short interest in May. As of May 15th, there was short interest totalling 30,255,708 shares, a decrease of 7.0% from the April 30th total of 32,530,055 shares. Based on an average daily volume of 1,660,800 shares, the days-to-cover ratio is presently 18.2 days. Approximately 25.3% of the company's stock are short sold.

Who are some of MannKind's key competitors?

Who are MannKind's key executives?

MannKind's management team includes the folowing people:
  • Dr. Michael E. Castagna, CEO & Director (Age 41)
  • Dr. David B. Thomson, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 55)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
  • Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)

Has MannKind been receiving favorable news coverage?

Media coverage about MNKD stock has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MannKind earned a coverage optimism score of 0.08 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are MannKind's major shareholders?

MannKind's stock is owned by a variety of of institutional and retail investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.57%), BlackRock Inc. (2.62%), Scopia Capital Management LP (0.81%), Millennium Management LLC (0.74%), Tibra Equities Europe Ltd (0.20%) and Dupont Capital Management Corp (0.20%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.

Which major investors are selling MannKind stock?

MNKD stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and BlackRock Inc.. View Insider Buying and Selling for MannKind.

Which major investors are buying MannKind stock?

MNKD stock was acquired by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Millennium Management LLC, Tibra Equities Europe Ltd, Element Capital Management LLC, Dupont Capital Management Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Rosabel Realica Alinaya and Stuart A Tross. View Insider Buying and Selling for MannKind.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $1.93.

How big of a company is MannKind?

MannKind has a market capitalization of $271.65 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]


MarketBeat Community Rating for MannKind (MNKD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  478 (Vote Underperform)
Total Votes:  846
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MannKind (NASDAQ:MNKD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for MannKind in the last 12 months. Their average twelve-month price target is $2.9233, suggesting that the stock has a possible upside of 51.47%. The high price target for MNKD is $5.00 and the low price target for MNKD is $1.00. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.001.501.751.75
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.9233$1.59$1.8850$0.9150
Price Target Upside: 51.47% upside49.68% downside28.33% downside71.85% downside

MannKind (NASDAQ:MNKD) Consensus Price Target History

Price Target History for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
2/28/2018Maxim GroupDowngradeHold ➝ Sell$1.00HighView Rating Details
1/25/2018S&P Equity ResearchLower Price Target$3.49 ➝ $2.77HighView Rating Details
5/22/2017JPMorgan Chase & Co.Reiterated RatingUnderweightHighView Rating Details
5/11/2017Piper Jaffray CompaniesSet Price TargetSell$1.00MediumView Rating Details
6/1/2016Royal Bank of CanadaLower Price TargetUnderperform$1.00 ➝ $0.15N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

MannKind (NASDAQ:MNKD) Earnings History and Estimates Chart

Earnings by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.83 EPS
Next Year EPS Consensus Estimate: $-0.65 EPS

MannKind (NASDAQ MNKD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/9/2018Q1 2018($0.23)($0.25)$3.53 million$3.47 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.29)($0.28)$3.22 million$4.53 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.20)($0.31)$2.56 million$2.04 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.25)($0.35)$2.75 million$2.16 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.09)($0.17)$3.50 million$3.00 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
10/29/2010Q3 2010($1.95)($2.00)ViewN/AView Earnings Details
8/2/2010Q2 2010($2.00)($1.87)ViewN/AView Earnings Details
4/30/2010Q1 2010($2.20)($1.98)ViewN/AView Earnings Details
2/1/2010Q4 2009($2.05)($2.64)ViewN/AView Earnings Details
11/2/2009Q3 2009($2.45)($2.10)ViewN/AView Earnings Details
8/3/2009Q2 2009($2.80)($2.72)ViewN/AView Earnings Details
5/4/2009Q1 2009($3.25)($2.91)ViewN/AView Earnings Details
2/17/2009Q4 2008($3.20)($4.10)ViewN/AView Earnings Details
11/5/2008Q3 2008($4.00)($3.37)ViewN/AView Earnings Details
8/11/2008Q2 2008($3.70)($3.94)ViewN/AView Earnings Details
5/5/2008Q1 2008($3.90)($3.52)ViewN/AView Earnings Details
3/4/2008Q4 2007($3.90)($3.77)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MannKind (NASDAQ:MNKD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MannKind (NASDAQ MNKD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 19.41%
Insider Trading History for MannKind (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2017Stuart A TrossVPBuy39,840$2.52$100,396.8059,840View SEC Filing  
12/20/2017Michael CastagnaCEOBuy8,000$2.29$18,320.0035,532View SEC Filing  
10/13/2017Kent KresaDirectorBuy166,600$6.00$999,600.00View SEC Filing  
8/10/2017Raymond W UrbanskiCMOSell296$1.15$340.402,924View SEC Filing  
6/30/2017Rosabel Realica AlinayaSVPBuy2,000$1.23$2,460.0030,091View SEC Filing  
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60403,085View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22140,456View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00212,500View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00195,000View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00180,000View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00397,996View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.0075,000View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.0050,000View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50139,024View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56158,858View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00139,450View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17729,685View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00139,450View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.0083,752View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57171,504View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00112,756View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.1240,082View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00136,016View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MannKind (NASDAQ MNKD) News Headlines

Source:
DateHeadline
MannKind Elder Abuse Is Replacing Inept CEO With FounderMannKind Elder Abuse Is Replacing Inept CEO With Founder
www.thestreet.com - May 25 at 5:00 PM
Is A New MannKind Possible?Is A New MannKind Possible?
seekingalpha.com - May 21 at 8:54 AM
MannKind - Afrezza Scripts Crack 500, But Growth Still Slower Than NeededMannKind - Afrezza Scripts Crack 500, But Growth Still Slower Than Needed
seekingalpha.com - May 20 at 9:12 AM
Form 4 MANNKIND CORP For: May 16 Filed by: Shannon James SamuelForm 4 MANNKIND CORP For: May 16 Filed by: Shannon James Samuel
www.streetinsider.com - May 18 at 5:01 PM
Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro ...Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro ...
globenewswire.com - May 17 at 9:14 AM
Is the Options Market Predicting a Spike in MannKind (MNKD) Stock?Is the Options Market Predicting a Spike in MannKind (MNKD) Stock?
finance.yahoo.com - May 16 at 4:52 PM
MannKind (MNKD) Upgraded by Zacks Investment Research to BuyMannKind (MNKD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 16 at 3:23 PM
MannKind (MNKD) Upgraded to "Sell" by BidaskClubMannKind (MNKD) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - May 16 at 10:30 AM
Is MannKind Guidance Plausible?Is MannKind Guidance Plausible?
seekingalpha.com - May 16 at 9:16 AM
MannKind Co. (MNKD) Sees Large Drop in Short InterestMannKind Co. (MNKD) Sees Large Drop in Short Interest
www.americanbankingnews.com - May 12 at 2:10 AM
MannKind (MNKD) Releases  Earnings Results, Misses Expectations By $0.02 EPSMannKind (MNKD) Releases Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 11 at 11:15 PM
MannKind - Scripts Dip, Cash, Q1 Call, And A DealMannKind - Scripts Dip, Cash, Q1 Call, And A Deal
seekingalpha.com - May 11 at 4:55 PM
Edited Transcript of MNKD earnings conference call or presentation 9-May-18 9:00pm GMTEdited Transcript of MNKD earnings conference call or presentation 9-May-18 9:00pm GMT
finance.yahoo.com - May 11 at 9:45 AM
MannKinds (MNKD) "Buy" Rating Reiterated at HC WainwrightMannKind's (MNKD) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - May 10 at 5:35 PM
Your Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed DataYour Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed Data
seekingalpha.com - May 10 at 5:02 PM
MannKind Inks Afrezza Deal With Cipla For IndiaMannKind Inks Afrezza Deal With Cipla For India
seekingalpha.com - May 10 at 5:02 PM
MannKind Q1 18 Earnings Conference Call At 5:00 PM ETMannKind Q1 18 Earnings Conference Call At 5:00 PM ET
www.nasdaq.com - May 10 at 9:16 AM
MannKinds (MNKD) CEO Michael Castagna on Q1 2018 Results - Earnings Call TranscriptMannKind's (MNKD) CEO Michael Castagna on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 9:16 AM
MannKind Q1 Results: The Good, the Bad, and the UglyMannKind Q1 Results: The Good, the Bad, and the Ugly
www.fool.com - May 10 at 6:51 AM
BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In IndiaBRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India
www.reuters.com - May 9 at 4:51 PM
BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In IndiaBRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India
www.reuters.com - May 9 at 4:51 PM
MannKind Corporation Reports 2018 First Quarter Financial ResultsMannKind Corporation Reports 2018 First Quarter Financial Results
finance.yahoo.com - May 9 at 4:51 PM
MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in IndiaMannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India
finance.yahoo.com - May 9 at 9:08 AM
Why MannKind Corporation Stock Broke Down in AprilWhy MannKind Corporation Stock Broke Down in April
finance.yahoo.com - May 8 at 9:02 AM
MannKind Earnings On Deck - What To Look ForMannKind Earnings On Deck - What To Look For
seekingalpha.com - May 7 at 4:57 PM
MannKind (MNKD) Scheduled to Post Earnings on WednesdayMannKind (MNKD) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 5 at 10:51 AM
MannKind - Afrezza Scripts Push Toward 500 As Quarterly Call ApproachesMannKind - Afrezza Scripts Push Toward 500 As Quarterly Call Approaches
seekingalpha.com - May 5 at 9:20 AM
MannKind Sees Meaningful Spike In Insurance CoverageMannKind Sees Meaningful Spike In Insurance Coverage
seekingalpha.com - May 4 at 4:45 PM
Free Research Reports on These Biotech Stocks -- MannKind, Marinus Pharma, Mirati Therapeutics, and OncoSec ...Free Research Reports on These Biotech Stocks -- MannKind, Marinus Pharma, Mirati Therapeutics, and OncoSec ...
www.prnewswire.com - May 4 at 9:00 AM
MannKind (MNKD) Upgraded at ValuEngineMannKind (MNKD) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 11:38 PM
MannKind (MNKD) Downgraded by Zacks Investment Research to "Hold"MannKind (MNKD) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 2 at 10:12 AM
MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018
finance.yahoo.com - May 2 at 9:02 AM
MannKind - Afrezza Scripts Trudge AlongMannKind - Afrezza Scripts Trudge Along
seekingalpha.com - April 28 at 9:24 AM
MannKind Co. (MNKD) Receives Consensus Rating of "Sell" from AnalystsMannKind Co. (MNKD) Receives Consensus Rating of "Sell" from Analysts
www.americanbankingnews.com - April 28 at 1:36 AM
MannKind (MNKD) Confirms FDA Determined Afrezza REMS Communication Plan Has Met Goals and REMS No ...MannKind (MNKD) Confirms FDA Determined Afrezza REMS Communication Plan Has Met Goals and REMS No ...
www.streetinsider.com - April 25 at 4:54 PM
MannKind Gets Some Positive FDA News Regarding AfrezzaMannKind Gets Some Positive FDA News Regarding Afrezza
seekingalpha.com - April 25 at 9:05 AM
MannKind +8% as FDA clears risk hurdles for AfrezzaMannKind +8% as FDA clears risk hurdles for Afrezza
seekingalpha.com - April 25 at 9:05 AM
MannKind - Afrezza Scripts Dip Again - Q2 Sales Underwhelming Thus FarMannKind - Afrezza Scripts Dip Again - Q2 Sales Underwhelming Thus Far
seekingalpha.com - April 20 at 4:46 PM
MannKind - Afrezza Scripts Dip Back Below 500MannKind - Afrezza Scripts Dip Back Below 500
seekingalpha.com - April 15 at 10:09 AM
MannKind (MNKD) Cut to "Hold" at ValuEngineMannKind (MNKD) Cut to "Hold" at ValuEngine
www.americanbankingnews.com - April 14 at 1:59 PM
MannKind (MNKD) Enters Oversold Territory April 13, 2018MannKind (MNKD) Enters Oversold Territory April 13, 2018
www.zacks.com - April 13 at 9:20 AM
MannKind (MNKD) Enters Oversold TerritoryMannKind (MNKD) Enters Oversold Territory
finance.yahoo.com - April 13 at 9:20 AM
MannKind And Its Cash SituationMannKind And Its Cash Situation
seekingalpha.com - April 11 at 4:48 PM
Form SC 13G MANNKIND CORP Filed by: SABBY MANAGEMENT, LLCForm SC 13G MANNKIND CORP Filed by: SABBY MANAGEMENT, LLC
www.streetinsider.com - April 9 at 4:44 PM
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? April 09, 2018Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? April 09, 2018
www.zacks.com - April 9 at 9:14 AM
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
finance.yahoo.com - April 9 at 9:14 AM
Why MannKind Corporation Stock Sank Last MonthWhy MannKind Corporation Stock Sank Last Month
finance.yahoo.com - April 9 at 9:14 AM
MannKind Raises $26.7 Million In Stock Offering - Not EnoughMannKind Raises $26.7 Million In Stock Offering - Not Enough
seekingalpha.com - April 8 at 5:08 PM
MannKind (MNKD) Rating Increased to Hold at Zacks Investment ResearchMannKind (MNKD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:50 PM
MannKind Modeling And Afrezza ScriptsMannKind Modeling And Afrezza Scripts
seekingalpha.com - April 7 at 9:30 AM

SEC Filings

MannKind (NASDAQ:MNKD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MannKind (NASDAQ:MNKD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MannKind (NASDAQ MNKD) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.